| Literature DB >> 28951630 |
Jun Wu1, Yawen Xiao2, Chao Xia1, Fan Yang3, Hua Li1, Zhifeng Shao1, Zongli Lin4, Xiaodong Zhao1.
Abstract
BACKGROUND: Lymph node (LN) metastasis was an independent risk factor for stomach cancer recurrence, and the presence of LN metastasis has great influence on the overall survival of stomach cancer patients. Thus, accurate prediction of the presence of lymph node metastasis can provide guarantee of credible prognosis evaluation of stomach cancer patients. Recently, increasing evidence demonstrated that the aberrant DNA methylation first appears before symptoms of the disease become clinically apparent.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28951630 PMCID: PMC5603126 DOI: 10.1155/2017/5745724
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Figure 1The density of the mean difference and BH-adjusted p value of the two comparisons. (a) The density of the mean difference of normal versus cancer comparison and LN negative versus LN positive comparison. (b) The density of the log10 BH-adjusted p value of normal versus cancer comparison and LN negative versus LN positive comparison.
Figure 2The distribution of mRMR scores with respect to features. The dashed line corresponds to the 10% cutoff used. (a) Normal versus cancer. (b) LN negative versus LN positive.
Figure 3The results of genetic algorithm-based feature selection with respect to the normal versus tumor classification. (a) The fitness improvement in the process of iteration. (b) The distribution of the number of selected probes.
Figure 4The results of genetic algorithm-based feature selection with respect to the LN negative versus LN positive classification. (b) The fitness improvement in the process of iteration. (a) The distribution of the number of selected probes.
Figure 5The distribution of the AUC value with different methods. (a) AUC value with different methods with respect to the normal versus tumor classification. (b) AUC value with different methods with respect to the LN negative versus LN positive classification.
The sample number for each phenotype.
| Normal | Cancer | ||
|---|---|---|---|
| LN negative | LN positive | Unclassified | |
| 27 | 94 | 189 | 12 |
Identified biomarkers for each prediction.
| Normal versus tumor biomarkers | LN negative versus LN positive biomarkers |
|---|---|
|
|
|